We have completed a third-party allotment of capital. While aiming to increase the number of N-NOSE tests and improve the consultation rate, we will promote our business with the immediate goal of putting the next-generation cancer type specific tests into practical use.
On Thursday, March 16, "DAVOS 2023 DEBRIEFING" was held by the Consulate of Switzerland in Osaka.Our CMO/CGO, Shunsuke Mizushima, was invited as . . .
2023.03.20HIROTSU BIO SCIENCE releases a cancer screening for “Pet Dogs”. “N-NOSE Dogs” Website now available. －Pre-order available, special discounts ar . . .
2023.03.10Our CEO made a courtesy call on Minister Yasutoshi Nishimura.
2023.02.27